ALK-negative anaplastic large cell lymphoma
MONDO:0017603ALK-negative anaplastic large cell lymphoma (ALK- ALCL) is a type of ALCL, a rare and aggressive peripheral T-cell non-Hodgkin lymphoma affecting lymph nodes and extranodal sites, which is characterized by the lack of expression of a protein called anaplastic lymphoma kinase (ALK).
Also known as: ALCL, ALK-, ALK- ALCL, ALK- anaplastic large cell lymphoma, ALK-negative anaplastic large cell lymphoma, anaplastic large cell lymphoma, ALK-negative
1967 clinical trials for this condition and its sub-types, 20 tagged with ALK-negative anaplastic large cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Could a stem cell boost keep T-Cell lymphoma away longer?
Disease control Recruiting nowThis study looks at whether giving high-dose chemotherapy followed by a transplant of the patient's own stem cells can help people with peripheral T-cell lymphoma stay in remission longer than just watching and waiting. About 294 adults aged 18 to 75 who are in their first comple…
Phase 3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…
Phase 3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Supercharged donor cells take on lymphoma in early trial
Disease control Recruiting nowThis early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost th…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New pill may keep rare lymphoma in check after chemo
Disease control Recruiting nowThis study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma (a rare blood cancer) from coming back after initial chemotherapy. About 136 adults who had a good response to first treatment but cannot or choose not to have a stem cell transplant will tak…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for tough lymphoma: stem cell transplant trial for Non-Responders
Disease control Recruiting nowThis study is for people with peripheral T-cell lymphoma whose cancer did not shrink or got worse after standard first treatment. It compares a stem cell transplant from a donor to other rescue treatments. The goal is to see which approach helps people live longer and control the…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a stem cell transplant stop T-Cell lymphoma from returning?
Disease control Recruiting nowThis study looks at whether a stem cell transplant (using a patient's own cells) after successful first treatment can help control peripheral T-cell lymphoma. About 160 people will either get the transplant or just be monitored. The goal is to see if the transplant delays the can…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Stem cell showdown: donor or self? new trial aims to improve lymphoma outcomes
Disease control Recruiting nowThis study compares two types of stem cell transplants for people with peripheral T-cell lymphoma whose cancer only partially responded to first treatment. One group receives their own stem cells, the other receives cells from a matched donor. The goal is to see which approach le…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists hunt for clues to tell apart two Look-Alike lymphomas
Knowledge-focused Recruiting nowThis study looks at rare lymphomas that are hard to tell apart under the microscope—some look like Hodgkin lymphoma but lack a key marker (PAX5), making them similar to another type called anaplastic large cell lymphoma (ALCL). Researchers will analyze tissue samples from 60 adul…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC